secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091777
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q2 revenue up 6% to $44.5M, net loss widens to $0.34/share, reaffirms FY guidance
--------------------------------------------------------------------------------

- Revenue $44.5M (+6% YoY); gross margin 80.2% vs 81.7% prior year.
- Net loss ($21.2M) or ($0.34)/share vs ($12.3M) or ($0.20)/share in Q2 2023.
- Adjusted EBITDA loss ($8.7M) vs ($7.7M) a year ago; cash & equivalents $97.0M.
- Full-year 2024 revenue guidance reaffirmed at $201M-$211M (7-13% growth); Adj. EBITDA expected to improve ~50%.
- CEO highlights planned entry into minimally invasive metatarsal osteotomy market in Q4 2024 and 65 granted U.S. patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024091777/0000950170-24-091777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024091777/tmci-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer